Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 23 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

61%

14 trials in Phase 3/4

Results Transparency

18%

3 of 17 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (1)
P 1 (2)
P 2 (2)
P 3 (8)
P 4 (6)

Trial Status

Completed17
Recruiting4
Unknown1
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT06855160Phase 3RecruitingPrimary

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

NCT06806137Phase 3RecruitingPrimary

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

NCT06740630Phase 3RecruitingPrimary

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

NCT05084508Phase 2CompletedPrimary

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

NCT06693895Phase 3RecruitingPrimary

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

NCT05732337Not ApplicableCompletedPrimary

Open Clinical Investigation to Evaluate the Effectiveness and Safety of a Topical Medical Device.

NCT04384016Phase 4CompletedPrimary

Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old

NCT00001054Phase 1Withdrawn

The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children

NCT00001125Phase 1Completed

Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox

NCT02570126Phase 3Completed

A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.

NCT00326183Phase 4Completed

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

NCT00921999CompletedPrimary

Immune Response to Varicella-Zoster Vaccination and Infection

NCT01887496CompletedPrimary

Varicella-related Hospitalizations in Turkey

NCT00156559CompletedPrimary

MMR and Varicella Vaccine in Premature Infants

NCT02452229Completed

Review of Human Herpes Viruses in Burns

NCT01982409Phase 4UnknownPrimary

Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children

NCT01815073Phase 4Completed

Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine

NCT01817270Phase 4CompletedPrimary

Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine

NCT01684072Phase 4CompletedPrimary

Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin

NCT00000953Phase 2Completed

Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients

Scroll to load more

Research Network

Activity Timeline